Hsu, P. (2018). Dual mTOR Kinase Inhibitor MLN0128 Sensitizes HR+/HER2+ Breast Cancer Patient-Derived Xenografts to Trastuzumab or Fulvestrant. The American Association for Cancer Research (AACR).
Chicago Style (17th ed.) CitationHsu, P.-Y. Dual MTOR Kinase Inhibitor MLN0128 Sensitizes HR+/HER2+ Breast Cancer Patient-Derived Xenografts to Trastuzumab or Fulvestrant. The American Association for Cancer Research (AACR), 2018.
MLA (9th ed.) CitationHsu, P.-Y. Dual MTOR Kinase Inhibitor MLN0128 Sensitizes HR+/HER2+ Breast Cancer Patient-Derived Xenografts to Trastuzumab or Fulvestrant. The American Association for Cancer Research (AACR), 2018.
Warning: These citations may not always be 100% accurate.